Related Experiment Video
Updated: May 13, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients
Chung-Feng Huang1, Chia-Yen Dai, Ming-Lun Yeh
1Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Background/Aims:
The impact of virological factors and interleukin-28B (IL-28B) genetic variants on retreatment of hepatitis C virus genotype 2 (HCV-2) treatment-experienced patients remains unknown.
Methods:
On-treatment virological responses and IL-28B rs8099917 genotype were determined in 46 HCV-2 treatment-experienced patients (42 previous relapsers; four previous non-responders) retreated with 24-week peginterferon/ribavirin.
Results:
Forty (87.0%) patients carried the rs8099917 TT genotype and 6 patients (13.0%) carried the TG/GG genotype. The sustained virological response (SVR; seronegativity of HCV RNA throughout 24 weeks of the post-treatment follow-up period) rate was 71.7%. Compared with previous non-responders, previous relapsers had a significantly higher SVR rate (78.6% vs. 0%, P = 0.004) and a lower relapse rate (17.5% vs. 100%, P = 0.04). All the previous non-responders were with the rs8099917 TT genotype. As for those who relapsed, treatment responses, including the rates of rapid virological response (RVR, 80.6% vs. 66.7%, P = 0.59), early virological response (EVR, 97.2% vs. 83.3%, P = 0.27), end-of-treatment virological response (97.2% vs. 83.3%, P = 0.27) and SVR (80.6% vs. 66.7%, P = 0.59) and relapse rate (17.1% vs. 20.0%, P = 1) did not differ significantly between patients with the rs8099917 TT and those with the non-TT genotype. Multivariate analysis revealed that the most important factor predictive of an SVR in the retreatment of HCV-2 was previous relapse; the only factor predictive of an SVR for previous relapsers was the achievement of an EVR. Compared with the achievement of a RVR, the attainment of an EVR was more accurate in predicting an SVR (88% vs. 74%).
Conclusions:
Peginterferon/ribavirin is effective in the retreatment of HCV-2 relapsers, especially among those who achieved an EVR.
Insights
Retreatment with peginterferon/ribavirin is effective for hepatitis C virus genotype 2 (HCV-2) relapsers. Achieving an early virological response (EVR) is key for sustained virological response (SVR) in these patients.
Area of Science:
- Hepatology
- Virology
- Genetics
Background:
- Hepatitis C virus genotype 2 (HCV-2) retreatment outcomes are not well understood.
- The role of virological factors and IL-28B rs8099917 genotype in HCV-2 retreatment is unclear.
Purpose of the Study:
- To investigate the impact of virological factors and IL-28B rs8099917 genotype on retreatment outcomes in HCV-2 patients.
- To evaluate the efficacy of peginterferon/ribavirin retreatment in treatment-experienced HCV-2 patients.
Main Methods:
- 46 HCV-2 treatment-experienced patients (42 relapsers, 4 non-responders) were retreated with 24-week peginterferon/ribavirin.
- On-treatment virological responses and IL-28B rs8099917 genotype were assessed.
Main Results:
- The overall sustained virological response (SVR) rate was 71.7%.
- Previous relapsers had significantly higher SVR rates (78.6%) compared to non-responders (0%).
- Early virological response (EVR) was a strong predictor of SVR, particularly in relapsers.
Conclusions:
- Peginterferon/ribavirin is effective for HCV-2 retreatment, especially for relapsers.
- Achieving an EVR is crucial for predicting SVR in patients undergoing retreatment for HCV-2.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Retroviruses

